These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37219426)

  • 1. Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii.
    Kon H; Hameir A; Nutman A; Temkin E; Keren Paz A; Lellouche J; Schwartz D; Weiss DS; Kaye KS; Daikos GL; Skiada A; Durante-Mangoni E; Dishon Benattar Y; Yahav D; Daitch V; Bernardo M; Iossa D; Friberg LE; Theuretzbacher U; Leibovici L; Dickstein Y; Pollak D; Mendelsohn S; Paul M; Carmeli Y
    Microbiol Spectr; 2023 Jun; 11(3):e0509322. PubMed ID: 37219426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heteroresistance to colistin in oxacillinase-producing carbapenem-resistant Acinetobacter baumannii clinical isolates from Gorgan, Northern Iran.
    Ezadi F; Jamali A; Heidari A; Javid N; Ardebili A
    J Glob Antimicrob Resist; 2020 Jun; 21():380-385. PubMed ID: 31770604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.
    Jain M; Sharma A; Sen MK; Rani V; Gaind R; Suri JC
    Microb Pathog; 2019 Mar; 128():75-81. PubMed ID: 30562602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
    Dickstein Y; Lellouche J; Ben Dalak Amar M; Schwartz D; Nutman A; Daitch V; Yahav D; Leibovici L; Skiada A; Antoniadou A; Daikos GL; Andini R; Zampino R; Durante-Mangoni E; Mouton JW; Friberg LE; Dishon Benattar Y; Bitterman R; Neuberger A; Carmeli Y; Paul M;
    Clin Infect Dis; 2019 Aug; 69(5):769-776. PubMed ID: 30462182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.
    Qureshi ZA; Hittle LE; O'Hara JA; Rivera JI; Syed A; Shields RK; Pasculle AW; Ernst RK; Doi Y
    Clin Infect Dis; 2015 May; 60(9):1295-303. PubMed ID: 25632010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colistin heteroresistance in carbapenem-resistant Acinetobacter baumannii clinical isolates from a Thai university hospital.
    Thet KT; Lunha K; Srisrattakarn A; Lulitanond A; Tavichakorntrakool R; Kuwatjanakul W; Charoensri N; Chanawong A
    World J Microbiol Biotechnol; 2020 Jul; 36(7):102. PubMed ID: 32613355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential Selection of Low-Frequency, Lipopolysaccharide-Modified, Colistin-Resistant Mutants with a Combination of Antimicrobials in Acinetobacter baumannii.
    Kamoshida G; Yamada N; Nakamura T; Yamaguchi D; Kai D; Yamashita M; Hayashi C; Kanda N; Sakaguchi M; Morimoto H; Sawada T; Okada T; Kaya Y; Takemoto N; Yahiro K
    Microbiol Spectr; 2022 Oct; 10(5):e0192822. PubMed ID: 36173297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of colistin against multidrug-resistant Acinetobacter baumannii isolates harboring blaOXA-23-like and blaOXA-24-like genes: A multicenter based study.
    Khanjani S; Sedigh Ebrahim-Saraie H; Shenagari M; Ashraf A; Mojtahedi A; Atrkar Roushan Z
    Acta Microbiol Immunol Hung; 2020 Mar; 67(3):182-186. PubMed ID: 32160785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Distribution of blaOXA genes in Acinetobacter baumannii strains: a multicenter study].
    Ciftci IH; Aşık G; Karakeçe E; Oksüz L; Yağcı S; Sesli Çetin E; Ozdemir M; Atasoy AR; Koçoğlu E; Gül M; Kurtoğlu MG; Köksal Çakırlar F; Seyrek A; Berktaş M; Gültepe B; Ayyildiz A
    Mikrobiyol Bul; 2013 Oct; 47(4):592-602. PubMed ID: 24237428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend.
    Balkhair A; Al-Muharrmi Z; Al'Adawi B; Al Busaidi I; Taher HB; Al-Siyabi T; Al Amin M; Hassan KS
    Int J Infect Dis; 2019 Aug; 85():10-15. PubMed ID: 31100418
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Soudeiha MAH; Dahdouh EA; Azar E; Sarkis DK; Daoud Z
    Front Cell Infect Microbiol; 2017; 7():209. PubMed ID: 28596943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.
    Cheng A; Chuang YC; Sun HY; Sheng WH; Yang CJ; Liao CH; Hsueh PR; Yang JL; Shen NJ; Wang JT; Hung CC; Chen YC; Chang SC
    Crit Care Med; 2015 Jun; 43(6):1194-204. PubMed ID: 25793437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the efficacy of colistin/sulbactam combination on carbapenem-resistant Acinetobacter baumannii strains].
    Çetinkol Y; Telli M; Altunçekiç Yıldırım A; Çalgın MK
    Mikrobiyol Bul; 2016 Jul; 50(3):460-5. PubMed ID: 27525401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii.
    Ni W; Wang Y; Ma X; He Y; Zhao J; Guan J; Li Y; Gao Z
    Eur J Clin Microbiol Infect Dis; 2022 Dec; 41(12):1451-1457. PubMed ID: 36201141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data.
    Oikonomou O; Sarrou S; Papagiannitsis CC; Georgiadou S; Mantzarlis K; Zakynthinos E; Dalekos GN; Petinaki E
    BMC Infect Dis; 2015 Dec; 15():559. PubMed ID: 26653099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of colistin heteroresistance in Acinetobacter baumannii from blood and respiratory isolates.
    Srinivas P; Hunt LN; Pouch SM; Thomas K; Goff DA; Pancholi P; Balada-Llasat JM; Bauer KA
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):194-198. PubMed ID: 29482871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
    J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii.
    Bian X; Liu X; Feng M; Bergen PJ; Li J; Chen Y; Zheng H; Song S; Zhang J
    Int J Antimicrob Agents; 2021 Feb; 57(2):106271. PubMed ID: 33352235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.
    Cai Y; Chai D; Wang R; Liang B; Bai N
    J Antimicrob Chemother; 2012 Jul; 67(7):1607-15. PubMed ID: 22441575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colistin heteroresistance in acinetobacter and its association with previous colistin therapy.
    Hawley JS; Murray CK; Jorgensen JH
    Antimicrob Agents Chemother; 2008 Jan; 52(1):351-2. PubMed ID: 17954699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.